A practical reference on storage stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Boxed warnings == Benzhydrocodone/APAP has the potential for addiction as well as abuse and misuse, which can result in overdose and death. Serious, life-threatening, or fatal respiratory depression can occur. Accidental ingestion can cause a fatal overdose of hydrocodone. Hydrocodone can cause neonatal opioid withdrawal syndrome when taken during pregnancy. Benzhydrocodone/APAP contains acetaminophen, which can cause acute liver failure at high doses (>4000 mg a day in healthy adults). Benzhydrocodone/APAP use with CYP3A4 inhibitors can cause a fatal overdose of hydrocodone. Benzhydrocodone/APAP use with benzodiazepines or other CNS depressants can cause sedation, respiratory depression, coma or death. Benzhydrocodone is a schedule II-controlled substance. Like other opioids, benzhydrocodone has the potential to be abused. Chronic benzhydrocodone use can lead to the development of tolerance and physical dependence. Withdrawal symptoms can occur from abrupt discontinuation or rapid tapering of benzhydrocodone.
There are small amounts of 238Pu in the plutonium from usual reactors. However, isotopic separation would be quite expensive compared to another method: when 235U captures a neutron, it is converted to an excited state of 236U. Some of the excited 236U nuclei undergo fission, but some decay to the ground state of 236U by emitting gamma radiation. Further neutron capture creates 237U; which, with a half-life of 7 days, decays to 237Np. Since nearly all neptunium is produced in this way or consists of isotopes that decay quickly, one gets nearly pure 237Np. After chemical separation of neptunium, 237Np is again irradiated by reactor neutrons to be converted to 238Np, which decays to 238Pu with a half-life of 2 days.
== Clinical significance == Insufficient secretion of vasopressin underlies diabetes insipidus, a condition in which the body loses the capacity to concentrate urine. Affected individuals excrete as much as 20 liters of dilute urine per day. Oversecretion of vasopressin causes the syndrome of inappropriate antidiuretic hormone (SIADH).
=== International === UEFA Cup Winners' Cup Runners-up: 1986–87 (Lost 0–1 to AFC Ajax) UEFA Cup Semi-finalist: 1973–74 International Football Cup (Intertoto Cup) Winners (1): 1965–66 Runners-up: 1964–65
Sources: en.wikipedia.org
Fyodor Dostoevsky's book The Idiot had a character, General Ivolgin, who witnessed and recounted his relationship with Napoleon during the Campaign of Russia. Roger Brook is a fictional secret agent and Napoleonic Wars Era gallant, later identified as the Chevalier de Breuc, in a series of twelve novels by Dennis Wheatley. The Hornblower books by C.S. Forester follow the naval career of Horatio Hornblower during the Napoleonic Wars. The 1951 film "Captain Horatio Hornblower" starring Gregory Peck and Virginia Mayo and directed by Raoul Walsh is a film adaption based on Forester's series of novels. Also by C.S. Forester two novels of the Peninsular War in Spain and Portugal: "Death to the French" (1932, published in the United States under the title "Rifleman Dodd"), and "The Gun" (1933), later made into a 1957 film, "The Pride and the Passion", with Cary Grant, Frank Sinatra, Sophia Loren, directed by Stanley Kramer. R. F. Delderfield, two novels about the Napoleonic Wars; Seven Men of Gascony (1949) about seven French infantrymen serving in a succession of Napoleonic campaigns, and Too Few For Drums (1964) about British soldiers cut off behind the French lines in Portugal in 1810, during the Peninsular War. The Aubrey–Maturin series of novels is a sequence of 20 historical novels by Patrick O'Brian portraying the rise of Jack Aubrey from Lieutenant to Rear Admiral during the Napoleonic Wars. The film Master and Commander: The Far Side of the World starring Russell Crowe and directed by Peter Weir is based on this series of books.
== Structure == Glutathione reductase from human erythrocytes is a homodimer consisting of 52kDa monomers, each containing 3 domains. GR exhibits single sheet, double layered topology where an anti-parallel beta-sheet is largely exposed to the solvent on one face while being covered by random coils on the other face. This includes and NADPH-binding Domain, FAD-binding domain(s) and a dimerization domain. Each monomer contains 478 residues and one FAD molecule. GR is a thermostable protein, retaining function up to 65 °C.
== Targets == A "target" is produced within the pharmaceutical industry. Generally, the "target" is the naturally existing cellular or molecular structure involved in the pathology of interest where the drug-in-development is meant to act. However, the distinction between a "new" and "established" target can be made without a full understanding of just what a "target" is. This distinction is typically made by pharmaceutical companies engaged in the discovery and development of therapeutics. In an estimate from 2011, 435 human genome products were identified as therapeutic drug targets of FDA-approved drugs. "Established targets" are those for which there is a good scientific understanding, supported by a lengthy publication history, of both how the target functions in normal physiology and how it is involved in human pathology. This does not imply that the mechanism of action of drugs that are thought to act through a particular established target is fully understood. Rather, "established" relates directly to the amount of background information available on a target, in particular functional information. In general, "new targets" are all those targets that are not "established targets" but which have been or are the subject of drug discovery efforts. The majority of targets selected for drug discovery efforts are proteins, such as G-protein-coupled receptors (GPCRs) and protein kinases.
Sources: en.wikipedia.org
Based on coalescence of Mitochondrial DNA and Y Chromosome data, the earliest extant lineages of modern humans on the Indian subcontinent had reached there from Africa between 80,000 and 50,000 years ago, and with high likelihood by 55,000 years ago. Neolithic and chalcolithic cultures arose in the western margins of the Indus river basin around Mehrgarh in Balochistan, Pakistan after 7000 BCE. These gradually evolved into the Indus Valley Civilisation, which flourished during 2500–1900 BCE in Pakistan and western India. Centred around cities such as Mohenjo-daro, Harappa and Dholavira, its characteristic features included steatite seals, a written script, urban planning, terracotta human figures and animal statuettes. Between 1500 BCE and 1200 BCE, an archaic form of Sanskrit, an Indo-European language, diffused into India from the northwest. Its evidence today is found in the Rig Veda—the scripture associated with the historical Vedic religion, one of the progenitors of what later became Hinduism. The settling of the Ganges river plain took place during the next millennium, when swathes of the river system's adjoining regions were deforested and prepared for agriculture. The Dravidian and other languages of India were supplanted in the north, creating a broad language family-divide, with the Indo-Aryan languages being spoken mainly in the north and west, and the Dravidian in some parts of east India and most of the south. A second urbanisation took place in India by the middle-first-millennium BCE.
The COMBINE project The ENVRI and ENVRIplus projects for common operations of environmental research infrastructures are developing the ENVRI Reference Model The Reference Architecture for Space Data Systems (RASDS) From the Consultative Committee for Space Data Systems. Interoperability Technology Association for Information Processing (INTAP), Japan. The European Advanced Informatics in Medicine (AIM) OpenLabs project. The Synapses European project. A 239-item reference list covering RM-ODP standards as well as related research, applications and case studies was included in.
Terpenes and terpenoids of many kinds are found in resinous plants such as the conifers. They are aromatic and serve to repel herbivores. Their scent makes them useful in essential oils, whether for perfumes such as rose and lavender, or for aromatherapy. Some have had medicinal uses: thymol is an antiseptic and was once used as a vermifuge (anti-worm medicine).
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.